An Open Label, Dose Escalation Study To Assess The Safety And Efficacy Of IL-22 Agonist F-652 In Patients With Alcoholic Hepatitis.
Interleukin-22 (IL-22) has beneficial effects on inflammation and impaired hepatic regeneration, that characterize AH. F-652 is a recombinant fusion protein of human IL-22 and IgG2-Fc. To assess safety and efficacy signals of F-652 in patients with moderate and severe AH. A phase-2 dose escalating study was carried out. F-652 (10, 30 or 45 μg/kg) administered on day-1 and 7 was tested in 3 patients each with moderate (MELD-scores:11-20) and severe AH (MELD-scores:21-28). Safety was defined by absence of serious adverse events (SAE) and efficacy was assessed by Lille score, changes in MELD score, and serum bilirubin and aminotransferases at days 28 and 42. Three independent propensity matched comparator patient cohorts were used. Plasma extracellular vesicles (EVs) and multiplex serum cytokines were measured to assess inflammation and hepatic regeneration. 18 patients (9 moderate and 9 severe AH) were enrolled, 66% male, mean age 48 years. The half-life of F-652 following the first dose was 61-85 hours. There were no SAE leading to discontinuation. MELD score, and serum aminotransferases decreased significantly at days 28 and 42 from baseline (p<0.05). Day-7 Lille score was ≤0.45 in 83% patients as compared with 6%,12%, and 56% among the comparator cohorts. EV counts decreased significantly at day-28 (p<0.013). Cytokine inflammatory markers were downregulated, and regeneration markers were upregulated at days 28 and 42. F-652 is safe in doses up to 45 μg/kg and associated with high rate of improvement as determined by Lille and MELD scores, reductions in markers of inflammation and increases in markers of hepatic regeneration. This study supports the need for randomized placebo-controlled trials to test efficacy of F-652 in AH.